Drug intelligence / Profile preview

cannabidivarinic acid

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Topical

Overview

Cannabidivarinic acid (CBDVA) is a non-psychoactive cannabinoid acid found in cannabis plants. It is the precursor to cannabidivarin (CBDV) and has been studied for its potential therapeutic properties, including anti-inflammatory, anti-emetic, and anti-convulsant effects. CBDVA is of interest for managing conditions such as seizures, inflammatory disorders, and nausea.

Other names: CBDVA

Targets

DAGLA (Diacylglycerol lipase alpha)

Beyond the preview

Go deeper on cannabidivarinic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cannabidivarinic acid.

Explore the full profile